*Some Market data delayed by 15 mins.

Regulus Therapeutics Inc.

Symbol: RGLS (NASDAQ)
2.01 ▲ (0.25%) 0.005

Company Description:
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.

Key Stats
  • Today's Open: $2
  • Today's High: $2.075
  • Today's Low: $1.965
  • Today's Volume: 219.07K
  • Yesterday Close: $2
  • Yesterday High: $2.1
  • Yesterday Low: $1.95
  • Yesterday Volume: 263.46K
  • Last Min Volume: 2.42K
  • Last Min High: $2.005
  • Last Min Low: $2.005
  • Last Min VWAP: $2.005
Company Profile
  • Name: Regulus Therapeutics Inc.
  • Website: https://www.regulusrx.com
  • Listed Date: 2012-10-04
  • Location: SAN DIEGO, CA
  • Market Status: Active
  • CIK Number: 0001505512
  • SIC Code: 2834
  • SIC description: PHARMACEUTICAL PREPARATIONS
  • Market Cap: $131.59M
  • Round Lot: 100
  • Outstanding Shares: 65.47M
  • Asset Type: CS
RECENT FILINGS FOR RGLS
Filing DateFiling TypeFormat
2024-05-20S-8View
2024-05-174View
2024-05-174View
2024-05-174View
2024-05-174View
2024-05-174View
2024-05-174View
2024-05-174View
2024-05-174View
2024-05-178-KView
2024-05-09424B5View
2024-05-0910-QView
2024-05-098-KView
2024-04-30DEFA14AView
2024-04-19EFFECTView
2024-04-19ARSView
2024-04-19DEF 14AView
2024-04-17CORRESPView
2024-04-16UPLOADView
2024-04-10SC 13G/AView
Latest News

 

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money. Copyright© 2024, 247MarketNews inc.